日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

ALPL-1是骨肉瘤嵌合抗原受体疗法的靶点

Nadia Mensali ,Hakan Köksal # ,Sandy Joaquina # ,Patrik Wernhoff ,Nicholas P Casey ,Paola Romecin ,Carla Panisello ,René Rodriguez ,Lene Vimeux ,Asta Juzeniene ,Marit R Myhre ,Anne Fåne ,Carolina Castilla Ramírez ,Solrun Melkorka Maggadottir ,Adil Doganay Duru ,Anna-Maria Georgoudaki ,Iwona Grad ,Andrés Daniel Maturana ,Gustav Gaudernack ,Gunnar Kvalheim ,Angel M Carcaboso ,Enrique de Alava ,Emmanuel Donnadieu ,Øyvind S Bruland ,Pablo Menendez ,Else Marit Inderberg ,Sébastien Wälchli

Age-related differences in the occurrence, severity, and distress of symptoms in older patients at the initiation of chemotherapy

老年患者在开始化疗时,症状的发生、严重程度和痛苦程度存在与年龄相关的差异

Johannessen, Marlen Sunde; Miaskowski, Christine; Kleven, Anne Grethe; Ritchie, Christine Seel; Paul, Steven M; Grov, Ellen Karine; Hareide, Martine; Gaudernack, Henrik; Utne, Inger

Therapeutic cancer vaccination against telomerase: clinical developments in melanoma

针对端粒酶的治疗性癌症疫苗:黑色素瘤的临床进展

Ellingsen, Espen Basmo; Bjørheim, Jens; Gaudernack, Gustav

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

接种长肽癌症疫苗 UV1 后持久且动态的 hTERT 免疫反应:三项 I 期临床试验的长期随访

Espen Basmo Ellingsen, Elin Aamdal, Tormod Guren, Wolfgang Lilleby, Paal F Brunsvig, Sara M Mangsbo, Steinar Aamdal, Eivind Hovig, Nadia Mensali, Gustav Gaudernack, Else Marit Inderberg0

Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants

个性化HLA分型有助于发现新的HLA等位基因和肿瘤特异性HLA变异体。

Anzar, Irantzu; Sverchkova, Angelina; Samarakoon, Pubudu; Ellingsen, Espen Basmo; Gaudernack, Gustav; Stratford, Richard; Clancy, Trevor

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy

利用 HLA II 类限制性 TCR 靶向端粒酶进行癌症免疫治疗

Pierre Dillard, Hakan Köksal, Solrun Melkorka Maggadottir, Anna Winge-Main, Sylvie Pollmann, Mathilde Menard, Marit Renée Myhre, Gunhild M Mælandsmo, Vivi Ann Flørenes, Gustav Gaudernack, Gunnar Kvalheim, Sébastien Wälchli, Else Marit Inderberg

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

利用HLA II类限制性T细胞受体靶向KRAS突变治疗实体瘤

Dillard, Pierre; Casey, Nicholas; Pollmann, Sylvie; Vernhoff, Patrik; Gaudernack, Gustav; Kvalheim, Gunnar; Wälchli, Sébastien; Inderberg, Else Marit

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

端粒酶作为癌症治疗疫苗的靶点及其优化临床应用潜力的考量

Ellingsen, Espen Basmo; Mangsbo, Sara M; Hovig, Eivind; Gaudernack, Gustav

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

将通用端粒酶癌症疫苗与伊匹单抗联合用于转移性黑色素瘤患者 - I/IIa 期临床试验的五年随访

Elin Aamdal, Else Marit Inderberg, Espen Basmo Ellingsen, Wenche Rasch, Paal Fredrik Brunsvig, Steinar Aamdal, Karen-Marie Heintz, Daniel Vodák, Sigve Nakken, Eivind Hovig, Marta Nyakas, Tormod Kyrre Guren, Gustav Gaudernack

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

第二代端粒酶疫苗 UV1 对晚期非小细胞肺癌患者进行的 I 期研究的长期结果

Paal F Brunsvig, Tormod Kyrre Guren, Marta Nyakas, Claudius H Steinfeldt-Reisse, Wenche Rasch, Jon Amund Kyte, Hedvig Vidarsdotter Juul, Steinar Aamdal, Gustav Gaudernack, Else Marit Inderberg